Search

Your search keyword '"Nickening G"' showing total 3 results
Start Over Author "Nickening G" Topic registries
3 results on '"Nickening G"'

1. Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation.

Author

Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, Lurz P, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Loureiro R, Fam N, Frerker C, Gavazzoni M, Hausleiter J, Ho E, Juliard JM, Kaple R, Besler C, Kodali S, Kreidel F, Kuck KH, Latib A, Lauten A, Monivas V, Mehr M, Muntané-Carol G, Nazif T, Nickening G, Pedrazzini G, Philippon F, Pozzoli A, Praz F, Puri R, Rodés-Cabau J, Schäfer U, Schofer J, Sievert H, Tang GHL, Thiele H, Topilsky Y, Rommel KP, Delgado V, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Leon MB, Hahn RT, Bax JJ, Enriquez-Sarano M, and Maisano F

Subjects
Aged, Aged, 80 and over, Case-Control Studies, Echocardiography, Europe epidemiology, Female, Humans, Male, North America epidemiology, Tricuspid Valve diagnostic imaging, Tricuspid Valve Insufficiency drug therapy, Tricuspid Valve Insufficiency mortality, Cardiac Surgical Procedures mortality, Endovascular Procedures mortality, Registries, Tricuspid Valve surgery, Tricuspid Valve Insufficiency surgery
Abstract

Background: Tricuspid regurgitation is associated with increased rates of heart failure (HF) and mortality. Transcatheter tricuspid valve interventions (TTVI) are promising, but the clinical benefit is unknown., Objectives: The purpose of this study was to investigate the potential benefit of TTVI over medical therapy in a propensity score matched population., Methods: The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected 472 patients from 22 European and North American centers who underwent TTVI from 2016 to 2018. A control cohort formed by 2 large retrospective registries enrolling medically managed patients with ≥ moderate tricuspid regurgitation in Europe and North America (n = 1,179) were propensity score 1:1 matched (distance ± 0.2 SD) using age, EuroSCORE II, and systolic pulmonary artery pressure. Survival was tested with Cox regression analysis. Primary endpoint was 1-year mortality or HF rehospitalization or the composite., Results: After matching, 268 adequately matched pairs of patients were identified. Compared with control subjects, TTVI patients had lower 1-year mortality (23 ± 3% vs. 36 ± 3%; p = 0.001), rehospitalization (26 ± 3% vs. 47 ± 3%; p < 0.0001), and composite endpoint (32 ± 4% vs. 49 ± 3%; p = 0.0003). TTVI was associated with greater survival and freedom from HF rehospitalization (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46 to 0.79; p = 0.003 unadjusted), which remained significant after adjusting for sex, New York Heart Association functional class, right ventricular dysfunction, and atrial fibrillation (HR: 0.39; 95% CI: 0.26 to 0.59; p < 0.0001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.35; 95% CI: 0.23 to 0.54; p < 0.0001)., Conclusions: In this propensity-matched case-control study, TTVI is associated with greater survival and reduced HF rehospitalization compared with medical therapy alone. Randomized trials should be performed to confirm these results., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

2. Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry

Author

Taramasso M, Gavazzoni M, Pozzoli A, Alessandrini H, Latib A, Attinger-Toller A, Biasco L, Braun D, Brochet E, Connelly KA, de Bruijn S, Denti P, Deuschl F, Estevez-Louriero R, Fam N, Frerker C, Ho E, Juliard JM, Kaple R, Kodali S, Kreidel F, Kuck KH, Lauten A, Lurz J, Monivas V, Mehr M, Nazif T, Nickening G, Pedrazzini G, Praz F, Puri R, Rodes-Cabau J, Schafer U, Schofer J, Sievert H, Tang GHL, Khattab AA, Thiele H, Unterhuber M, Vahanian A, Von Bardeleben RS, Webb JG, Weber M, Windecker S, Winkel M, Zuber M, Hausleiter J, Lurz P, Maisano F, Leon MB, Hahn RT, Taramasso, M, Gavazzoni, M, Pozzoli, A, Alessandrini, H, Latib, A, Attinger-Toller, A, Biasco, L, Braun, D, Brochet, E, Connelly, Ka, de Bruijn, S, Denti, P, Deuschl, F, Estevez-Louriero, R, Fam, N, Frerker, C, Ho, E, Juliard, Jm, Kaple, R, Kodali, S, Kreidel, F, Kuck, Kh, Lauten, A, Lurz, J, Monivas, V, Mehr, M, Nazif, T, Nickening, G, Pedrazzini, G, Praz, F, Puri, R, Rodes-Cabau, J, Schafer, U, Schofer, J, Sievert, H, Tang, Ghl, Khattab, Aa, Thiele, H, Unterhuber, M, Vahanian, A, Von Bardeleben, R, Webb, Jg, Weber, M, Windecker, S, Winkel, M, Zuber, M, Hausleiter, J, Lurz, P, Maisano, F, Leon, Mb, and Hahn, Rt

Subjects
Male, Cardiac Catheterization, Pacemaker, Artificial, Time Factors, Clinical Decision-Making, Electric Countershock, Prosthesis Design, Postoperative Complications, Risk Factors, Humans, Hospital Mortality, Registries, 610 Medicine & health, Retrospective Studies, Aged, 80 and over, Heart Valve Prosthesis Implantation, Cardiac Pacing, Artificial, Hemodynamics, Mitral Valve Insufficiency, Recovery of Function, Defibrillators, Implantable, Europe, Treatment Outcome, Heart Valve Prosthesis, North America, Feasibility Studies, Mitral Valve, Female
Abstract

OBJECTIVES The interference of a transtricuspid cardiac implantable electronic device (CIED) lead with tricuspid valve function may contribute to the mechanism of tricuspid regurgitation (TR) and poses specific therapeutic challenges during transcatheter tricuspid valve intervention (TTVI). Feasibility and efficacy of TTVI in presence of a CIED is unclear. BACKGROUND Feasibility of TTVI in presence of a CIED lead has never been proven on a large basis. METHODS The study population consisted of 470 patients with severe symptomatic TR from the TriValve (Transcatheter Tricuspid Valve Therapies) registry who underwent TTVI at 21 centers between 2015 and 2018. The association of CIED and outcomes were assessed. RESULTS Pre-procedural CIED was present in 121 of 470 (25.7%) patients. The most frequent location of the CIED lead was the posteroseptal commissure (44.0%). As compared with patients without a transvalvular lead (no-CIED group), patients having a tricuspid lead (CIED group) were more symptomatic (New York Heart Association functional class III to IV in 95.9% vs. 92.3%; p = 0.02) and more frequently had previous episodes of right heart failure (87.8% vs. 69.0%; p = 0.002). No-CIED patients had more severe TR (effective regurgitant orifice area 0.7 ± 0.6 cm2 vs. 0.6 ± 0.3 cm2; p = 0.02), but significantly better right ventricular function (tricuspid annular plane systolic excursion = 16.7 ± 5.0 mm vs. 15.9 ± 4.0 mm; p = 0.04). Overall, 373 patients (79%) were treated with the MitraClip (Abbott Vascular, Santa Clara, California) (106 [87.0%] in the CIED group). Among them, 154 (33%) patients had concomitant transcatheter mitral repair (55 [46.0%] in the CIED group, all MitraClip). Procedural success was achieved in 80.0% of no-CIED patients and in 78.6% of CIED patients (p = 0.74), with an in-hospital mortality of 2.9% and 3.7%, respectively (p = 0.70). At 30 days, residual TR ≤2+ was observed in 70.8% of no-CIED and in 73.7% of CIED patients (p = 0.6). Symptomatic improvement was observed in both groups (NYHA functional class I to II at 30 days: 66.0% vs. 65.0%; p = 0.30). Survival at 12 months was 80.7 ± 3.0% in the no-CIED patients and 73.6 ± 5.0% in the CIED patients (p = 0.30). CONCLUSIONS TTVI is feasible in selected patients with CIED leads and acute procedural success and short-term clinical outcomes are comparable to those observed in patients without a transtricuspid lead.

Published
2019

3. Transcatheter Versus Medical Treatment of Patients With Symptomatic Severe Tricuspid Regurgitation

Author

Josep Rodés-Cabau, Stephan Windecker, Jeroen J. Bax, Florian Deuschl, Luigi Biasco, Maurizio Taramasso, Eric Brochet, Kim A. Connelly, Michael Mehr, Giovanni Benfari, Alberto Pozzoli, Ryan Kaple, Fabien Praz, Christian Besler, Mirjam Winkel, Christian Frerker, François Philippon, Sabine de Bruijn, Rishi Puri, Alexander Lauten, Ralph Stephan von Bardeleben, Georg Nickening, Azeem Latib, Neil Fam, Alec Vahanian, John G. Webb, Rodrigo Estevez-Loureiro, Horst Sievert, Tamin Nazif, Karl Philipp Rommel, Mara Gavazzoni, Guillem Muntané-Carol, Giovanni Pedrazzini, Philipp Lurz, Felix Kreidel, Adrian Attinger-Toller, Susheel Kodali, Paolo Denti, Vanessa Moñivas, Daniel Braun, Rebecca T. Hahn, Pieter van der Bijl, Jean Michel Juliard, Jörg Hausleiter, Hannes Alessandrini, Maurice Enriquez-Sarano, Karl-Heinz Kuck, Marcel Weber, Michel Zuber, Yan Topilsky, Gilbert H.L. Tang, Holger Thiele, Francesco Maisano, Edwin C. Ho, Martin B. Leon, Victoria Delgado, Joachim Schofer, Ulrich Schäfer, Taramasso, M, Benfari, G, van der Bijl, P, Alessandrini, H, Attinger-Toller, A, Biasco, L, Lurz, P, Braun, D, Brochet, E, Connelly, Ka, de Bruijn, S, Denti, P, Deuschl, F, Estevez-Loureiro, R, Fam, N, Frerker, C, Gavazzoni, M, Hausleiter, J, Ho, E, Juliard, Jm, Kaple, R, Besler, C, Kodali, S, Kreidel, F, Kuck, Kh, Latib, A, Lauten, A, Monivas, V, Mehr, M, Muntane-Carol, G, Nazif, T, Nickening, G, Pedrazzini, G, Philippon, F, Pozzoli, A, Praz, F, Puri, R, Rodes-Cabau, J, Schafer, U, Schofer, J, Sievert, H, Tang, Ghl, Thiele, H, Topilsky, Y, Rommel, Kp, Delgado, V, Vahanian, A, Von Bardeleben, R, Webb, Jg, Weber, M, Windecker, S, Winkel, M, Zuber, M, Leon, Mb, Hahn, Rt, Bax, Jj, Enriquez-Sarano, M, and Maisano, F

Subjects
Male, medicine.medical_specialty, Valve Repaire, Population, Tricuspid regurgitation, 030204 cardiovascular system & hematology, tricuspid valve, heart valve diseases, law.invention, 03 medical and health sciences, Native Valvular Regurgitation, 0302 clinical medicine, Randomized controlled trial, law, tricuspid regurgitation, Internal medicine, Tricuspid valve, medicine, Clinical endpoint, Humans, Registries, 030212 general & internal medicine, Cardiac Surgical Procedures, education, 610 Medicine & health, Aged, Aged, 80 and over, education.field_of_study, business.industry, Proportional hazards model, Endovascular Procedures, Heart valve diseases, medicine.disease, Tricuspid Valve Insufficiency, Europe, medicine.anatomical_structure, Echocardiography, Case-Control Studies, Heart failure, North America, Propensity score matching, Cohort, Cardiology, Female, Cardiology and Cardiovascular Medicine, business
Abstract

BACKGROUND Tricuspid regurgitation is associated with increased rates of heart failure (HF) and mortality. Transcatheter tricuspid valve interventions (TTVI) are promising, but the clinical benefit is unknown. OBJECTIVES The purpose of this study was to investigate the potential benefit of TTVI over medical therapy in a propensity score matched population. METHODS The TriValve (Transcatheter Tricuspid Valve Therapies) registry collected 472 patients from 22 European and North American centers who underwent TTVI from 2016 to 2018. A control cohort formed by 2 large retrospective registries enrolling medically managed patients with >= moderate tricuspid regurgitation in Europe and North America (n = 1,179) were propensity score 1:1 matched (distance +/- 0.2 SD) using age, EuroSCORE II, and systolic pulmonary artery pressure. Survival was tested with Cox regression analysis. Primary endpoint was 1-year mortality or HF rehospitalization or the composite. RESULTS After matching, 268 adequately matched pairs of patients were identified. Compared with control subjects, TTVI patients had lower 1-year mortality (23 +/- 3% vs. 36 +/- 3%; p = 0.001), rehospitalization (26 +/- 3% vs. 47 +/- 3%; p < 0.0001), and composite endpoint (32 +/- 4% vs. 49 +/- 3%; p = 0.0003). TTVI was associated with greater survival and freedom from HF rehospitalization (hazard ratio [HR]: 0.60; 95% confidence interval [CI]: 0.46 to 0.79; p = 0.003 unadjusted), which remained significant after adjusting for sex, New York Heart Association functional class, right ventricular dysfunction, and atrial fibrillation (HR: 0.39; 95% CI: 0.26 to 0.59; p < 0.0001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.35; 95% CI: 0.23 to 0.54; p < 0.0001). CONCLUSIONS In this propensity-matched case-control study, TTVI is associated with greater survival and reduced HF rehospitalization compared with medical therapy alone. Randomized trials should be performed to confirm these results. (C) 2019 by the American College of Cardiology Foundation.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results